Syngene Extends Strategic Partnership with Bristol Myers Squibb Until 2035

Syngene International has extended its long-term research collaboration with Bristol Myers Squibb until 2035. The expanded agreement broadens integrated services across the drug development lifecycle. This collaboration aims to enhance capabilities, infrastructure, and support for Bristol Myers Squibb's discovery and development programs, reinforcing their position as strategic partners.

Syngene International announced on Monday the extension of its strategic research collaboration with Bristol Myers Squibb through 2035. This long-term agreement broadens the scope of integrated services across various stages of the drug development lifecycle, including discovery, translational sciences, pharmaceutical development, manufacturing, clinical trials, and information technology services. This extension ensures a seamless transition from research to commercialization.

The collaboration marks a significant phase of growth for Syngene, solidifying its role as a key partner in the delivery of integrated scientific and manufacturing solutions. Managing Director and CEO of Syngene International, Peter Bains, expressed enthusiasm about extending this partnership, which began over 25 years ago, emphasizing the focus on scientific excellence and innovative therapies.

This decade-long extension provides the opportunity for both companies to plan and build new capabilities and infrastructure to support Bristol Myers Squibb's future discovery and development programs. The expanded collaboration reaffirms commitments to scientific advancement and the acceleration of transformative medicines that improve patient outcomes worldwide.

(With inputs from agencies.)